Literature DB >> 18706500

Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation.

Diana M Girnita1, Gilbert Burckart, Adriana Zeevi.   

Abstract

Consolidating the information that we have on pharmacogenetics and on cytokine genetics to produce patient-oriented individualized drug regimens is an important challenge in transplantation medicine. Using a multi-variant approach based on genetic profile and other relevant clinical factors a score system may be developed to predict the severity of rejection, infection, or other complications associated with transplantation. The ultimate goal of these studies is to improve patient outcome through individualized drug regimens.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18706500      PMCID： PMC2739872          DOI： 10.1016/j.coi.2008.08.002

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  79 in total

1.  Immune response gene polymorphisms in renal transplant recipients.

Authors:  Svetlana Dmitrienko; David I Hoar; Robert Balshaw; Paul A Keown
Journal:  Transplantation       Date:  2005-12-27       Impact factor: 4.939

2.  IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease.

Authors:  Lidia Karabon; Barbara Wysoczanska; Katarzyna Bogunia-Kubik; Krzysztof Suchnicki; Andrzej Lange
Journal:  Hum Immunol       Date:  2005-03-19       Impact factor: 2.850

Review 3.  Interleukin-1 polymorphisms and graft-vs-host disease.

Authors:  Hannah Cullup; Gail Stark
Journal:  Leuk Lymphoma       Date:  2005-04

4.  ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.

Authors:  Ingeborg A Hauser; Elke Schaeffeler; Stefan Gauer; Ernst H Scheuermann; Binytha Wegner; Jan Gossmann; Hanns Ackermann; Christian Seidl; Berthold Hocher; Ulrich M Zanger; Helmut Geiger; Michel Eichelbaum; Matthias Schwab
Journal:  J Am Soc Nephrol       Date:  2005-03-16       Impact factor: 10.121

5.  The beneficial effects of recipient-derived vascular endothelial growth factor on graft survival after kidney transplantation.

Authors:  Francine B C Lemos; Wendy M Mol; Joke I Roodnat; André Uitterlinden; Jan N M Ijzermans; Willem Weimar; Carla C Baan
Journal:  Transplantation       Date:  2005-05-15       Impact factor: 4.939

6.  Impact of TGFbeta1 gene polymorphisms on acute and chronic rejection in pediatric heart transplant allografts.

Authors:  Sylvie Di Filippo; Adriana Zeevi; Kevin K McDade; Olivier Bastien; Steven A Webber
Journal:  Transplantation       Date:  2006-03-27       Impact factor: 4.939

7.  Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation.

Authors:  K W Seo; D H Kim; S K Sohn; N Y Lee; H H Chang; S W Kim; S B Jeon; J H Baek; J G Kim; J S Suh; K B Lee
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

8.  Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation.

Authors:  Songfeng Yu; Lihua Wu; Jing Jin; Sheng Yan; Guoping Jiang; Haiyang Xie; Shusen Zheng
Journal:  Transplantation       Date:  2006-01-15       Impact factor: 4.939

9.  Interleukin-6 polymorphism: a genetic risk factor for cardiac transplant related coronary vasculopathy?

Authors:  Cameron G Densem; Michele Ray; Ian V Hutchinson; Nizar Yonan; Nicholas H Brooks
Journal:  J Heart Lung Transplant       Date:  2005-05       Impact factor: 10.247

10.  Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation.

Authors:  Pam Kimball; Melissa Baker; Robert A Fisher
Journal:  Liver Transpl       Date:  2006-02       Impact factor: 5.799
View more
  5 in total

1.  Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.

Authors:  Xiaoqing Zhang; Zhaowen Wang; Junwei Fan; Gaolin Liu; Zhihai Peng
Journal:  Eur J Clin Pharmacol       Date:  2011-02-26       Impact factor: 2.953

Review 2.  Institutional shared resources and translational cancer research.

Authors:  Paolo De Paoli
Journal:  J Transl Med       Date:  2009-06-29       Impact factor: 5.531

3.  Predicting the risk for corneal graft rejection by aqueous humor analysis.

Authors:  Philip Maier; Ulrike Heizmann; Daniel Böhringer; Yvonne Kern; Thomas Reinhard
Journal:  Mol Vis       Date:  2011-04-25       Impact factor: 2.367

4.  The Polymorphism -308G/A of Tumor Necrosis Factor-α Gene Modulates the Effect of Immunosuppressive Treatment in First Kidney Transplant Subjects Who Suffer an Acute Rejection.

Authors:  Ana Isabel Sánchez-Fructuoso; Isabel Pérez-Flores; Rosalia Valero; Maria Angeles Moreno; Miguel Fernandez-Arquero; Elena Urcelay; Cristina Fernández-Pérez; Jose Luis Santiago
Journal:  J Immunol Res       Date:  2016-09-29       Impact factor: 4.818

Review 5.  Review: immunosuppression for the lung transplant patient.

Authors:  Sakhee Kotecha; Steven Ivulich; Gregory Snell
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.